Comment by gojomo

The environment in which Theranos operates is highly regulated, often to the benefit of entrenched/concentrated incumbent providers rather than consumers.

So throwing in a little reminder that a cheaper/faster/on-demand offering has a 'right-of-access' dimension may be useful, as a balance against any FUD/appeals-to-traditional-gatekeeper-authority, coming from other slower/higher-cost providers.

They do say the right is for "access to...", rather than for "free provision of...".